Trial Profile
A Multicentre, Open-label Phase II Study of Irinotecan, Capecitabine(Xeloda), and Oxaliplatin (IXO) as First Line Treatment in Patients With Metastatic Gastric or Gastroesophageal (GEJ) Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2022
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Oxaliplatin (Primary) ; Capecitabine
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms IXOGoo1
- 22 Feb 2019 Status changed from active, no longer recruiting to completed.
- 04 Jan 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jan 2016 ).
- 07 Jan 2016 Planned End Date changed from 1 Jul 2015 to 1 Jan 2018 ClinicalTrials.gov record.